Patents by Inventor Matthew A. Nugent

Matthew A. Nugent has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20080227752
    Abstract: The present invention is directed to methods for inhibition of histone acetyltransferases using glycosaminoglycans. The invention is further directed to methods for treating disorders associated with hyperacetylation by administration of glycosaminoglycans to a patient in need thereof. In one preferred embodiment, the glycosaminoglycan is a heparin or heparan sulfate oligosaccharide. Studies show that removal of sulfate residues from the O-positions of either the uronic acid or the glucosamine did not eliminate the inhibitory activity of heparan sulfate. Since a majority of heparan sulfate binding proteins appear to require O-sulfation, molecules without certain O-sulfations can be used to inhibit HATs while not interacting with most known heparin-binding proteins. In addition, specific sequences of heparin/heparan sulfate can be used to specifically inhibit various HATs.
    Type: Application
    Filed: June 28, 2005
    Publication date: September 18, 2008
    Applicant: Trustees of Boston University
    Inventors: Matthew A. Nugent, Edward Hsia, Jo Ann Buczek-Thomas
  • Patent number: 5766584
    Abstract: A composition and method are provided for inhibition of vascular smooth muscle cell proliferation following injury to the endothelial cell lining of a blood vessel such as resulting from angioplasty, vascular bypass surgery or organ transplantation. The composition is a matrix such as a biodegradable hydrogel made of a synthetic polymer, protein or polysaccharide seeded with vascular endothelial cells which can be xenografts, allografts or autografts, or genetically engineered cells. Attachment of cells to the matrix can be enhanced by coating with collagen, laminin, fibronectin, fibrin, basement membrane components or attachment peptides. Biologically active compounds such as anti-inflammatory agents may also be contained in the matrix. In the method, the matrix containing endothelial cells is implanted in a patient at a site adjacent the injury such as by wrapping the matrix around the blood vessel.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: June 16, 1998
    Assignee: Massachusetts Institute of Technology
    Inventors: Elazer R. Edelman, Aruna Nathan, Matthew A. Nugent
  • Patent number: 5567417
    Abstract: Pharmaceutical compositions for delivering an effective dose to a desired site of a heparinase. These compositions are based on the discovery that heparinase alone can inhibit angiogenesis. The effective dosage is dependent not only on the heparinase, but also on the method and means of delivery, which can be localized or systemic. For example, in some applications, as in the treatment of psoriasis or diabetic retinopathy, the inhibitor is delivered in a topical ophthalmic carrier. In other applications, as in the treatment of solid tumors, the inhibitor is delivered by means of a biodegradable, polymeric implant.
    Type: Grant
    Filed: May 1, 1995
    Date of Patent: October 22, 1996
    Assignees: Massachusetts Institute of Technology, Children's Medical Center Corporation
    Inventors: Ramnath Sasisekharan, Marsha A. Moses, Matthew A. Nugent, Charles L. Cooney, Robert S. Langer